Amarin | AMRN - Net Income


Amarin reported $-7.74M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Novartis USD 3.93B 96M Sep/2025